Ann: Mesoblast Appoints Dr Eric Rose as Chief Medical Officer, page-59

Here's a question for everyone.
what would you do if you have inventory worth $~30m USD with a shelf life and one of your customers operating say in Japan was using that same product in their country!
imagine if you could use all the data from say that country for your own clinical trials??

if mesoblast had any real concerns about FDA approval then they might just sell it!
their actions speak clearly to the intent they are building for commercial approval.

With Eric now in an executive role and his background he can become more hands on. Having just completed the AICD course it gives me a better understanding of the real different roles the board plays verses senior management. What's surprised me, is it took so long for him to move into that role!

a few alluded to the fact silviu might be difficult to work with, well guess what, Eric knows exactly how he operates and has gone into the role. If anything it also says he could step up to CEO should silviu achieve his dream of product approval.
one of the key roles of directors is to ensure succession planning is in place and this is identified in the annual statements on page 29 " risks related to our business and industry"